Project PERCH brings together 18 European countries and 34 partner organizations with the objective of contributing to the implementation of Europe’s Beating Cancer Plan. PERCH aligns with the World Health Organization’s (WHO) “90-70-90” strategy, aiming to achieve at least 90% HPV vaccination coverage among girls, and potentially boys, by the age of 15 years.
Project objectives are:
Subscribe to PERCH newsletter and get the latest updates from European Partnership to Contrast HPV
As part of Work Package 4 (WP4) Integration and Sustainability and Work Package 2 (WP2) Communication and Dissemination, the PERCH initiative aims to improve the capacity of European Member States
The UICC World Cancer Congress recently hosted a digital session titled “Cervical Cancer Elimination: Local and European Experiences for Global Learnings.” This session addressed the urgent need to eliminate cervical
As part of Work Package 4 (WP4) Integration and Sustainability and Work Package 2 (WP2) Communication and Dissemination, the PERCH initiative aims to improve the capacity of European Member States
The UICC World Cancer Congress recently hosted a digital session titled “Cervical Cancer Elimination: Local and European Experiences for Global Learnings.” This session addressed the urgent need to eliminate cervical
As part of Work Package 4 (WP4) Integration and Sustainability and Work Package 2 (WP2) Communication and Dissemination, the PERCH initiative aims to improve the capacity of European Member States (MS) to effectively plan and implement HPV vaccination actions and campaigns. Task 4.6 (WP4) focuses on the launch of vaccination
The UICC World Cancer Congress recently hosted a digital session titled “Cervical Cancer Elimination: Local and European Experiences for Global Learnings.” This session addressed the urgent need to eliminate cervical cancer, a preventable disease that still claims the lives of women worldwide due to significant disparities in healthcare access and
Human Papilloma infections prevention. The european Joint Action partnERschip to contrast HPV (PERCH) and e-lerning for the health professionals – Papillomavirus (HPV) infection is the most common sexually transmitted infection (in both sexes). Vaccines against HPV have been available since 2006 and although they have been progressively introduced in
On June 21, the Council of the European Union took an important step in the fight against cancer by adopting a Council Recommendation on vaccine-preventable cancers. This recommendation, originally proposed by the European Commission on January 31, is an important part of Europe’s Beating Cancer Plan. It aims to improve
PERCH General Assembly Timing: 09th December 2024, 10:00 – 18:00 CET Paris in presence and remotely Meeting Chair: Istituto Superiore di Sanità (ISS) Participants: – Consortium partners – Scientific Advisory Board (SAB) members – Governmental Advisory Board (GAB) members Download AGENDA
The PERCH WP2 meeting produced valuable results On 24 and 25 April 2024, health and communication experts from the PERCH partner countries met in person in Ljubljana and via Zoom. The main purpose of the PERCH WP2 meeting was to facilitate discussions and collaboration between the participating countries on the
On 17 November 2023 PERCH met students, teachers and parents from some schools in Basilicata participating in the Project to address aspects relating to HPV and its prevention.
The meetings will also continue in other Italian regions involved in the PERCH project.
On 13 November 2023 PERCH met students, teachers and parents from some schools in Puglia participating in the Project to address aspects relating to HPV and its prevention.
The meetings will also continue in other Italian regions involved in the PERCH project.
Subscribe to PERCH newsletter and get the latest updates from European Partnership to Contrast HPV
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not re!ect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.
